Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484004 | 0.87 | L3MBTL1 (0.41) | PARP1HDAC8HDAC6MEN1KMT2A | |
| SCHEMBL4092403 | 0.84 | PARP1 (0.53) | PARP1HDAC8HDAC6SMN1; SMN2MEN1 | |
| SCHEMBL5825205 | 0.81 | TPMT (0.46) | PARP1KMT2AHPGDPOLBNPC1 | |
| SCHEMBL3898425 | 0.79 | HDAC8 (0.50) | PARP1HDAC8HDAC6SMN1; SMN2MEN1 | |
| SCHEMBL5824834 | 0.79 | PARP1 (0.52) | PARP1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL571813 | 0.79 | CES2 (0.55) | PARP1HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3054202 | 0.79 | PARP1 (0.52) | PARP1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL5824521 | 0.78 | CES2 (0.59) | PARP1SMN1; SMN2MEN1KMT2AKCNK3 | |
| SCHEMBL10802915 | 0.77 | PARP1 (0.59) | PARP1HDAC8HDAC6SMN1; SMN2MEN1 | |
| SCHEMBL2892447 | 0.77 | ALDH1A1 (0.48) | HDAC6SMN1; SMN2MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059901-A | 1,3, 4-Oxadiazole compound and preparation method and application thereof | 成都大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-118146109-A | Method for synthesizing N-trifluoromethyl secondary amide compound from benzoyl isothiocyanate | 南京理工大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-2200977-B1 | F1F0-ATPASE INHIBITORS AND RELATED METHODS | UNIV MICHIGAN (US) | 2016-11-09 | — | — | EP | disclosed |
| CN-102516144-B | Thiourea compound and preparation thereof and application thereof to metal ore floatation | UNIV CENTRAL SOUTH | 2014-11-05 | — | — | CN | disclosed |
| CN-101855203-B | F1F0Inhibitors of ATP synthase and related methods | UNIV MICHIGAN | 2014-03-19 | — | — | CN | disclosed |
| US-20130158111-A1 | Compositions and Methods for Depleting Mutant p53 | GEORGETOWN UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| US-8324258-B2 | F1F0-ATPase inhibitors and related methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-12-04 | — | — | US | disclosed |
| CN-101855203-A | F1F0Inhibitors of ATP synthase and related methods | UNIV MICHIGAN | 2010-10-06 | — | — | CN | disclosed |
| US-20100222400-A1 | F1F0-ATPase Inhibitors and Related Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-09-02 | — | — | US | disclosed |
| EP-2200977-A2 | F1F0-ATPASE INHIBITORS AND RELATED METHODS | The Regents of the University of Michigan (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009036175-A2 | F1F0-ATPASE INHIBITORS AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-03-19 | — | — | WO | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
| US-5084457-A | Cognition activators and nervous system disorders | AMERICAN CYANAMID COMPANY (US) | 1992-01-28 | — | — | US | disclosed |
| US-5001157-A | Substituted N-[[2-(aminocarbonyl)phenylamino]thioxomethyl]benzamides | AMERICAN CYANAMID COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PARP1 828/4885HDAC8 3866/4885HDAC6 2895/4885 |
| US-20100222400-A1 | F1F0-ATPase Inhibitors and Related Methods | ATP5F1A, ATP5F1B, ATP5F1D | PARP1 1171/4885HDAC8 2067/4885HDAC6 1788/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PARP1 1112/4885HDAC8 2920/4885HDAC6 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.